{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:34:51Z","timestamp":1791423291535,"version":"4.3.3"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejphar.2024.177095","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T08:00:46Z","timestamp":1730880046000},"page":"177095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["The power of three: Retatrutide's role in modern obesity and diabetes therapy"],"prefix":"10.1016","volume":"985","author":[{"given":"Toufik","family":"Abdul-Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poulami","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Kamal","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann Ludwig","family":"Mueller-Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarmistha","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Oluwafemi","family":"Femi-Lawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Awuah","family":"Wireko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala Ibrahim","family":"Thaalibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Usman","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Sefenu","family":"Dzebu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sewar Basheer","family":"Banimusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7404-890X","authenticated-orcid":false,"given":"Aayushi","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejphar.2024.177095_bib1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1210\/jc.2010-2435","article-title":"Impaired regulation of the incretin effect in patients with type 2 diabetes","volume":"96","author":"Bagger","year":"2011","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.ejphar.2024.177095_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101090","article-title":"Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease","volume":"46","author":"Baggio","year":"2021","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejphar.2024.177095_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2024.171149","article-title":"Recent advances in peptide-based therapies for obesity and type 2 diabetes","volume":"173","author":"Bailey","year":"2024","journal-title":"Peptides"},{"issue":"4","key":"10.1016\/j.ejphar.2024.177095_bib4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2337\/diacare.19.4.394","article-title":"Fatty Acids and insulin resistance","volume":"19","author":"Boden","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2024.177095_bib5","series-title":"Semaglutide Dominates GLP-1 Receptor Agonist Clinical Trials","author":"Buntz","year":"2024"},{"key":"10.1016\/j.ejphar.2024.177095_bib6","first-page":"989","article-title":"Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy - focus on alogliptin","volume":"7","author":"Capuano","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejphar.2024.177095_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101882","article-title":"Pharmacotherapy of obesity: an update on the available medications and drugs under investigation","volume":"58","author":"Chakhtoura","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ejphar.2024.177095_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metabol."},{"issue":"9","key":"10.1016\/j.ejphar.2024.177095_bib9","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metabol."},{"issue":"7","key":"10.1016\/j.ejphar.2024.177095_bib10","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/BF03346357","article-title":"Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in type 2 diabetes management","volume":"30","author":"Crepaldi","year":"2007","journal-title":"J. Endocrinol. Invest."},{"issue":"15","key":"10.1016\/j.ejphar.2024.177095_bib11","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1517\/14656566.2013.824966","article-title":"Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety","volume":"14","author":"Deacon","year":"2013","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejphar.2024.177095_bib12","doi-asserted-by":"crossref","unstructured":"Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty zucker rats | Diabetes | American Diabetes Association. (n.d.). Retrieved September 8, 2024, from https:\/\/diabetesjournals.org\/diabetes\/article\/50\/5\/1004\/11353\/Defective-Glucose-Dependent-Insulinotropic.","DOI":"10.2337\/diabetes.50.5.1004"},{"issue":"5","key":"10.1016\/j.ejphar.2024.177095_bib13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/13543784.2023.2206560","article-title":"Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?","volume":"32","author":"Doggrell","year":"2023","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"1","key":"10.1016\/j.ejphar.2024.177095_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents","volume":"21","author":"Finan","year":"2015","journal-title":"Nat. Med."},{"issue":"10258","key":"10.1016\/j.ejphar.2024.177095_bib15","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"396","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"7","key":"10.1016\/j.ejphar.2024.177095_bib16","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/14656566.2024.2356254","article-title":"Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?","volume":"25","author":"Gogineni","year":"2024","journal-title":"Expet Opin. Pharmacother."},{"issue":"11","key":"10.1016\/j.ejphar.2024.177095_bib17","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/dom.12958","article-title":"Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes","volume":"19","author":"Guzman","year":"2017","journal-title":"Diabetes Obes. Metabol."},{"issue":"1","key":"10.1016\/j.ejphar.2024.177095_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3803\/EnM.2024.1942","article-title":"The road towards triple agonists: glucagon-like peptide 1, glucose-dependent Insulinotropic polypeptide and glucagon receptor - an Update","volume":"39","author":"Jakubowska","year":"2024","journal-title":"Endocrinology and Metabolism (Seoul, Korea)"},{"issue":"6","key":"10.1016\/j.ejphar.2024.177095_bib19","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple\u2013hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2024.177095_bib20","first-page":"A234","article-title":"A cross-sectional analysis of NEFA Levels following a standard mixed meal in a population of persons with newly diagnosed type 2 diabetes mellitus across a spectrum of glycemic control","volume":"56","author":"Jelic","year":"2007","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.ejphar.2024.177095_bib21","first-page":"4047","article-title":"Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes","volume":"86","author":"Kahn","year":"2001","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"11","key":"10.1016\/j.ejphar.2024.177095_bib22","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/diab.42.11.1663","article-title":"Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function","volume":"42","author":"Kahn","year":"1993","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.ejphar.2024.177095_bib23","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.2337\/db11-0425","article-title":"Fatty acids, obesity, and insulin resistance: time for a reevaluation","volume":"60","author":"Karpe","year":"2011","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.ejphar.2024.177095_bib24","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00228-024-03646-0","article-title":"A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity","volume":"80","author":"Kaur","year":"2024","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.ejphar.2024.177095_bib25","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/ijo.2008.102","article-title":"Global burden of obesity in 2005 and projections to 2030","volume":"32","author":"Kelly","year":"2008","journal-title":"Int. J. Obes."},{"issue":"1","key":"10.1016\/j.ejphar.2024.177095_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-024-00700-0","article-title":"Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide","volume":"10","author":"Li","year":"2024","journal-title":"Cell Discovery"},{"issue":"8738","key":"10.1016\/j.ejphar.2024.177095_bib27","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/0140-6736(91)91164-P","article-title":"Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians","volume":"337","author":"McKeigue","year":"1991","journal-title":"Lancet (London, England)"},{"issue":"9","key":"10.1016\/j.ejphar.2024.177095_bib28","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.metabol.2015.05.012","article-title":"Incretin-based therapies for obesity treatment","volume":"64","author":"Mello","year":"2015","journal-title":"Metab., Clin. Exp."},{"issue":"9945","key":"10.1016\/j.ejphar.2024.177095_bib29","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0140-6736(14)60460-8","article-title":"Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the global burden of disease study 2013","volume":"384","author":"Ng","year":"2014","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejphar.2024.177095_bib30","unstructured":"Obesity and overweight. (n.d.). Retrieved September 8, 2024, from https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"10.1016\/j.ejphar.2024.177095_bib31","doi-asserted-by":"crossref","unstructured":"Obesity epidemiology. Frank B Hu. | International Journal of Epidemiology | Oxford Academic. (n.d.). Retrieved September 8, 2024, from https:\/\/academic.oup.com\/ije\/article\/38\/1\/325\/696929.","DOI":"10.1093\/ije\/dyn227"},{"key":"10.1016\/j.ejphar.2024.177095_bib32","unstructured":"Prescription medications to treat overweight & obesity\u2014NIDDK. (n.d.). National Institute of Diabetes and digestive and kidney diseases. Retrieved September 8, 2024, from https:\/\/www.niddk.nih.gov\/health-information\/weight-management\/prescription-medications-treat-overweight-obesity."},{"issue":"11","key":"10.1016\/j.ejphar.2024.177095_bib33","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/13543784.2023.2276754","article-title":"Retatrutide: a triple incretin receptor agonist for obesity management","volume":"32","author":"Ray","year":"2023","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"4","key":"10.1016\/j.ejphar.2024.177095_bib34","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1210\/endo.140.4.6643","article-title":"Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion","volume":"140","author":"Rocca","year":"1999","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.ejphar.2024.177095_bib35","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1172\/JCI118742","article-title":"Mechanism of free fatty acid-induced insulin resistance in humans","volume":"97","author":"Roden","year":"1996","journal-title":"J. Clin. Invest."},{"issue":"10401","key":"10.1016\/j.ejphar.2024.177095_bib36","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet (London, England)"},{"issue":"12","key":"10.1016\/j.ejphar.2024.177095_bib37","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146353","article-title":"GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice","volume":"131","author":"Samms","year":"2021","journal-title":"J. Clin. Investig."},{"issue":"7","key":"10.1016\/j.ejphar.2024.177095_bib38","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2024.177095_bib39","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1478-7954-10-22","article-title":"National, regional, and global trends in adult overweight and obesity prevalences","volume":"10","author":"Stevens","year":"2012","journal-title":"Popul. Health Metrics"},{"key":"10.1016\/j.ejphar.2024.177095_bib40","unstructured":"Study Details | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight | ClinicalTrials.gov. (n.d.). Retrieved September 8, 2024, from https:\/\/clinicaltrials.gov\/study\/NCT05929066."},{"issue":"4","key":"10.1016\/j.ejphar.2024.177095_bib41","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2265.1974.tb02820.x","article-title":"The effect of the intestinal polypeptides, Irp and Gip, on insulin|release and glucose tolerance in the baboon","volume":"3","author":"Turner","year":"1974","journal-title":"Clin. Endocrinol."},{"issue":"10366","key":"10.1016\/j.ejphar.2024.177095_bib42","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0140-6736(22)02033-5","article-title":"LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial","volume":"400","author":"Urva","year":"2022","journal-title":"Lancet (London, England)"},{"issue":"9","key":"10.1016\/j.ejphar.2024.177095_bib43","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1111\/dom.15167","article-title":"The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying","volume":"25","author":"Urva","year":"2023","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2024.177095_bib44","article-title":"GLP\u22121 receptor agonists for the treatment of obesity: role as a promising approach","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.ejphar.2024.177095_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/cells13010065","article-title":"GLP1 receptor agonists\u2014effects beyond obesity and diabetes","volume":"13","author":"Wilbon","year":"2024","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.ejphar.2024.177095_bib46","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.cmet.2021.01.015","article-title":"The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling","volume":"33","author":"Zhang","year":"2021","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejphar.2024.177095_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Endocrinol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924007854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924007854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T01:28:50Z","timestamp":1733621330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299924007854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":47,"alternative-id":["S0014299924007854"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.177095","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The power of three: Retatrutide's role in modern obesity and diabetes therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.177095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"177095"}}